Status: Recruiting
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.
Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Oncolytics BiotechUpdated: Jun 8, 2026Locations: 3
Eligibility criteria
Histologically confirmed cancer of the colon or rectum with documented metastasi... [+10]
Undergone systemic chemotherapy, radiotherapy, or surgery, <4 weeks before study... [+11]